Highlights Newsletter 1

This newsletter presents you the following key sessions:

1. Podcast with prof. Michael Hofman about the phase II TheraP trial: Lutetium 177-labeled PSMA-617 in
    metastatic castration-resistant prostate cancer

2. Imaging-related irradiation can safely be reduced in patients with stage 1 seminoma following orchiectomy

3. Enfortumab vedotin induces a complete response in one out of five patients with cisplatin-ineligible,
    advanced urothelial carcinoma with previous PD-1/L1 exposure

4. Lenvatinib plus pembrolizumab as frontline treatment for patients with advanced clear-cell renal cell
    carcinoma

5. Combination therapy with pembrolizumab, docetaxel and prednisone for previously treated metastatic,
    castration-resistant prostate cancer